 Niacinamide
"Niacinamide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and PELLAGRA. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake.
| Descriptor ID |
D009536
|
| MeSH Number(s) |
D03.066.515.530 D03.383.725.547.530
|
| Concept/Terms |
Niacinamide- Niacinamide
- Vitamin PP
- Vitamin B 3
- B 3, Vitamin
- Vitamin B3
- B3, Vitamin
- 3-Pyridinecarboxamide
- 3 Pyridinecarboxamide
- Nicotinamide
Papulex- Papulex
- Pharmagenix Brand of Niacinamide
- Niacinamide Pharmagenix Brand
Nicotinsäureamid Jenapharm- Nicotinsäureamid Jenapharm
- Jenapharm, Nicotinsäureamid
- Jenapharm Brand of Niacinamide
- Niacinamide Jenapharm Brand
Nicobion- Nicobion
- Merck Brand of Niacinamide
- Niacinamide Merck Brand
- Astra Brand of Niacinamide
- Niacinamide Astra Brand
|
Below are MeSH descriptors whose meaning is more general than "Niacinamide".
Below are MeSH descriptors whose meaning is more specific than "Niacinamide".
This graph shows the total number of publications written about "Niacinamide" by people in this website by year, and whether "Niacinamide" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1983 | 0 | 1 | 1 | | 1984 | 0 | 1 | 1 | | 1993 | 0 | 1 | 1 | | 2010 | 0 | 4 | 4 | | 2012 | 1 | 0 | 1 | | 2013 | 0 | 2 | 2 | | 2014 | 1 | 0 | 1 | | 2015 | 0 | 1 | 1 | | 2016 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Niacinamide" by people in Profiles.
-
Grunwald MR, McDonnell MH, Induru R, Gerber JM. Cutaneous manifestations in leukemia patients. Semin Oncol. 2016 06; 43(3):359-65.
-
Nostro MC, Sarangi F, Yang C, Holland A, Elefanty AG, Stanley EG, Greiner DL, Keller G. Efficient generation of NKX6-1+ pancreatic progenitors from multiple human pluripotent stem cell lines. Stem Cell Reports. 2015 Apr 14; 4(4):591-604.
-
Nguyen TV, Sleiman M, Moriarty T, Herrick WG, Peyton SR. Sorafenib resistance and JNK signaling in carcinoma during extracellular matrix stiffening. Biomaterials. 2014 Jul; 35(22):5749-59.
-
Schwartzberg LS, Tauer KW, Hermann RC, Makari-Judson G, Isaacs C, Beck JT, Kaklamani V, Stepanski EJ, Rugo HS, Wang W, Bell-McGuinn K, Kirshner JJ, Eisenberg P, Emanuelson R, Keaton M, Levine E, Medgyesy DC, Qamar R, Starr A, Ro SK, Lokker NA, Hudis CA. Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. Clin Cancer Res. 2013 May 15; 19(10):2745-54.
-
Venkateshaiah SU, Khan S, Ling W, Bam R, Li X, van Rhee F, Usmani S, Barlogie B, Epstein J, Yaccoby S. NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity. Exp Hematol. 2013 Jun; 41(6):547-557.e2.
-
Den RB, Kamrava M, Sheng Z, Werner-Wasik M, Dougherty E, Marinucchi M, Lawrence YR, Hegarty S, Hyslop T, Andrews DW, Glass J, Friedman DP, Green MR, Camphausen K, Dicker AP. A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas. Int J Radiat Oncol Biol Phys. 2013 Feb 1; 85(2):321-8.
-
Saidi RF, Shah SA, Rawson AP, Grossman S, Piperdi B, Bozorgzadeh A. Treating hepatocellular carcinoma with sorafenib in liver transplant patients: an initial experience. Transplant Proc. 2010 Dec; 42(10):4582-4.
-
Walker AK, Yang F, Jiang K, Ji JY, Watts JL, Purushotham A, Boss O, Hirsch ML, Ribich S, Smith JJ, Israelian K, Westphal CH, Rodgers JT, Shioda T, Elson SL, Mulligan P, Najafi-Shoushtari H, Black JC, Thakur JK, Kadyk LC, Whetstine JR, Mostoslavsky R, Puigserver P, Li X, Dyson NJ, Hart AC, Näär AM. Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP. Genes Dev. 2010 Jul 01; 24(13):1403-17.
-
Sheng Z, Li L, Zhu LJ, Smith TW, Demers A, Ross AH, Moser RP, Green MR. A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications. Nat Med. 2010 Jun; 16(6):671-7.
-
Siegelin MD, Raskett CM, Gilbert CA, Ross AH, Altieri DC. Sorafenib exerts anti-glioma activity in vitro and in vivo. Neurosci Lett. 2010 Jul 12; 478(3):165-70.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|